In a recent article on the Jewish Journal website (http://dtn.fm/DhxK8), doctors, dignitaries and officials representing Israel and California convened at Cedars-Sinai Medical Center on February 8, 2016, to witness the signing of an agreement between Israel’s Ministry of Science and … Continue reading →

International Stem Cell Corp. (OTCQB: ISCO) is considered among industry experts as a leader and pioneer in the field of regenerative medicine as a result of its development of a new class of stem cells. These cells, known as human … Continue reading →

Parkinson’s disease is caused by death of dopamine-producing cells in a brain region called the substantia nigra, which hampers movement. Current treatments focus primarily on replacing the lost dopamine, but these treatments eventually fail because the dopamine-making cells continue to … Continue reading →

International Stem Cell Corp. (OTCQB: ISCO) builds shareholder value through the development of restorative medicine using stem cell technology. Through its innovative parthenogenesis technology, the company makes use of human stem cells from unfertilized oocytes (eggs), bypassing common ethical controversy … Continue reading →

A California-based biotechnology company, International Stem Cell Corporation (OTCQB: ISCO) focuses its energies on developing restorative medicine using stem cell technology. Its innovative parthenogenesis technology uses human stem cells derived from unfertilized oocytes (eggs), which helps the company avoid any … Continue reading →

International Stem Cell Corporation (OTCQB: ISCO) is the company behind a powerful new stem cell technology called parthenogenesis, which promises to significantly advance the field of regenerative medicine by addressing the problem of immune-rejection. Derived from unfertilized eggs, the company’s … Continue reading →

As part of its quest to successfully develop stem cells for research and therapy, the International Stem Cell Corporation (OTCQB: ISCO) has been using a powerful new stem cell technology to address the problem of immune-rejection. Most recently, the Carlsbad, … Continue reading →

International Stem Cell Corporation (OTCQB: ISCO), a clinical stage biotechnology company developing novel stem cell-based therapies, recently announced that it has entered into an agreement with the Florey Institute of Neuroscience and Mental Health (Florey) to conduct a Phase I/IIa … Continue reading →

International Stem Cell Corporation (OTCQB: ISCO) has its fingers in many pies. It develops and markets products in three different lines, and two of those businesses turn a profit. Its biomedical division is the most profitable. For the nine months … Continue reading →

With the recent announcement from Australia’s version of the FDA, the Therapeutic Goods Administration, that pluripotent stem cell manufacturing innovator International Stem Cell Corp. (OTCQB: ISCO) has been cleared to start Phase I/IIa dose escalation clinical trials focused on the … Continue reading →